Gene Biotherapeutics Inc. (CRXM)
Stock Price: $0.0510 USD
0.0110 (27.50%)
Updated Feb 26, 2021 10:38 AM EST - Market open
| Market Cap | 1.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.85M |
| Shares Out | 14.05M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $0.0510 |
| Previous Close | $0.0400 |
| Change ($) | 0.0110 |
| Change (%) | 27.50% |
| Day's Open | 0.0485 |
| Day's Range | 0.0450 - 0.0510 |
| Day's Volume | 810,367 |
| 52-Week Range | 0.0204 - 0.17 |
News
There are no news available yet.
About CRXM
Gene Biotherapeutics manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platfor... [Read more...]
| Industry Biotechnology | Founded 2003 |
| CEO Christopher Reinhard | Employees 6 |
| Stock Exchange OTCMKTS | Ticker Symbol CRXM |